$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2012 Q2 Form 10-Q Financial Statement

#000110465912036030 Filed on May 11, 2012

Income Statement

Concept	2012 Q2	2012 Q1	2011 Q1
Revenue	$10.64M	$7.774M	$5.966M
YoY Change	163.29%	30.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.820M	$4.100M	$4.400M
YoY Change	-13.39%	-6.82%	11.96%
% of Gross Profit
Research & Development	$13.72M	$14.00M	$11.13M
YoY Change	18.12%	25.88%	25.14%
% of Gross Profit
Depreciation & Amortization	$440.0K	$420.0K	$440.0K
YoY Change	4.76%	-4.55%	-18.52%
% of Gross Profit
Operating Expenses	$19.98M	$18.52M	$15.97M
YoY Change	6.5%	16.0%	19.59%
Operating Profit	-$9.347M	-$10.75M	-$9.999M
YoY Change	-36.52%	7.46%
Interest Expense	$15.00K	$43.00K	$48.00K
YoY Change	-63.41%	-10.42%	-71.76%
% of Operating Profit
Other Income/Expense, Net	$21.00K	$0.00	$70.00K
YoY Change		-100.0%
Pretax Income	-$9.343M	-$13.14M	-$13.35M
YoY Change	-26.09%	-1.6%	1.29%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.343M	-$13.14M	-$13.35M
YoY Change	-26.09%	-1.6%	1.29%
Net Earnings / Revenue	-87.83%	-168.99%	-223.77%
Basic Earnings Per Share
Diluted Earnings Per Share	-$199.3K	-$346.8K	-$387.0K
COMMON SHARES
Basic Shares Outstanding	46.38M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q2	2012 Q1	2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.80M	$108.2M	$93.80M
YoY Change	15.42%	15.35%	15.23%
Cash & Equivalents	$28.86M	$24.52M	$27.66M
Short-Term Investments	$66.90M	$83.70M	$66.10M
Other Short-Term Assets	$2.700M	$2.789M	$2.300M
YoY Change	-12.9%	21.26%	-8.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$105.7M	$115.3M	$100.0M
YoY Change	19.98%	15.29%	19.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.500M	$5.073M	$2.200M
YoY Change	189.47%	130.59%	-43.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$442.0K	$300.0K
YoY Change	33.33%	47.33%	0.0%
Total Long-Term Assets	$5.900M	$5.515M	$2.600M
YoY Change	168.18%	112.12%	-38.1%
TOTAL ASSETS
Total Short-Term Assets	$105.7M	$115.3M	$100.0M
Total Long-Term Assets	$5.900M	$5.515M	$2.600M
Total Assets	$111.6M	$120.8M	$102.6M
YoY Change	23.59%	17.74%	16.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.100M	$8.400M	$7.400M
YoY Change	30.0%	13.51%	0.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$800.0K	$1.100M	$1.300M
YoY Change	-38.46%	-15.38%	-13.33%
Total Short-Term Liabilities	$17.81M	$17.77M	$16.60M
YoY Change	5.4%	7.02%	88.64%
LONG-TERM LIABILITIES
Long-Term Debt	$500.0K	$600.0K	$700.0K
YoY Change	25.0%	-14.29%	-65.0%
Other Long-Term Liabilities	$20.10M	$21.70M	$32.10M
YoY Change	-29.23%	-32.4%	935.48%
Total Long-Term Liabilities	$20.60M	$22.30M	$32.80M
YoY Change	-28.47%	-32.01%	543.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.81M	$17.77M	$16.60M
Total Long-Term Liabilities	$20.60M	$22.30M	$32.80M
Total Liabilities	$38.40M	$40.00M	$49.50M
YoY Change	-15.97%	-19.19%	256.12%
SHAREHOLDERS EQUITY
Retained Earnings		-$283.2M
YoY Change
Common Stock		$364.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$73.17M	$80.78M	$53.10M
YoY Change
Total Liabilities & Shareholders Equity	$111.6M	$120.8M	$102.6M
YoY Change	23.59%	17.74%	16.46%

Cashflow Statement

Concept	2012 Q2	2012 Q1	2011 Q1
OPERATING ACTIVITIES
Net Income	-$9.343M	-$13.14M	-$13.35M
YoY Change	-26.09%	-1.6%	1.29%
Depreciation, Depletion And Amortization	$440.0K	$420.0K	$440.0K
YoY Change	4.76%	-4.55%	-18.52%
Cash From Operating Activities	-$11.13M	-$8.040M	-$13.31M
YoY Change	5.0%	-39.59%	-0.89%
INVESTING ACTIVITIES
Capital Expenditures	-$860.0K	$3.082M	$71.00K
YoY Change	681.82%	4240.85%	-201.43%
Acquisitions
YoY Change
Other Investing Activities	$16.74M	-$53.61M	$11.79M
YoY Change	89.37%	-554.71%	7.47%
Cash From Investing Activities	$15.88M	-$56.69M	$11.72M
YoY Change	81.9%	-583.7%	7.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$62.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-410.0K	63.58M	-320.0K
YoY Change		-19968.75%	-101.91%
NET CHANGE
Cash From Operating Activities	-11.13M	-8.040M	-13.31M
Cash From Investing Activities	15.88M	-56.69M	11.72M
Cash From Financing Activities	-410.0K	63.58M	-320.0K
Net Change In Cash	4.340M	-1.150M	-1.910M
YoY Change	-332.09%	-39.79%	-113.43%
FREE CASH FLOW
Cash From Operating Activities	-$11.13M	-$8.040M	-$13.31M
Capital Expenditures	-$860.0K	$3.082M	$71.00K
Free Cash Flow	-$10.27M	-$11.12M	-$13.38M
YoY Change	-2.1%	-16.88%	0.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10745000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	18519000	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	420000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4095000	USD
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14004000	USD
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	7774000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-303467000	USD
CY2012Q1	fold	Collaboration Revenue CollaborationRevenue	1660000	USD
CY2011Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13350000	USD
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-13350000	USD
CY2011Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13350000	USD
CY2011Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	70000	USD
CY2011Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	59000	USD
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9999000	USD
CY2011Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1418000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1388000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	37125000	USD
CY2012Q1	fold	Share Based Compensation Non Emplyees ShareBasedCompensationNonEmplyees	0	USD
	fold	Share Based Compensation Non Emplyees ShareBasedCompensationNonEmplyees	853000	USD
CY2012Q1	fold	Stock Based License Payments StockBasedLicensePayments	0	USD
	fold	Stock Based License Payments StockBasedLicensePayments	1220000	USD
CY2011Q1	fold	Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities ChangeInFairValueOfWarrantLiabilityAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities	3432000	USD
CY2012Q1	fold	Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities ChangeInFairValueOfWarrantLiabilityAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities	2376000	USD
	fold	Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities ChangeInFairValueOfWarrantLiabilityAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities	1476000	USD
CY2012Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120801000	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	80776000	USD
CY2012Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283241000	USD
CY2012Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	37000	USD
CY2012Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	363456000	USD
CY2012Q1	us-gaap	Common Stock Value CommonStockValue	524000	USD
CY2012Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	597000	USD
CY2012Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	4324000	USD
CY2012Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	17339000	USD
CY2012Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17765000	USD
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9507000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	69795000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	29592000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270104000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	299285000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	407000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18999000	USD
CY2012Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	1129000	USD
CY2011Q1	us-gaap	Operating Expenses OperatingExpenses	15965000	USD
CY2011Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	438000	USD
CY2011Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4402000	USD
CY2011Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11125000	USD
CY2011Q1	us-gaap	Sales Revenue Net SalesRevenueNet	5966000	USD
CY2011Q1	fold	Collaboration Revenue CollaborationRevenue	1660000	USD
	fold	Research Revenue ResearchRevenue	52016000	USD
CY2012Q1	fold	Research Revenue ResearchRevenue	6114000	USD
CY2011Q1	fold	Research Revenue ResearchRevenue	4306000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37887520	shares
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19256000	USD
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	1044000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8504000	USD
CY2011Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9708000	USD
CY2011Q4	us-gaap	Assets Assets	69795000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	709000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2438000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	66648000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5903000	USD
CY2011Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5043000	USD
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	30034000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25668000	USD
CY2012Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46376169	shares
CY2012Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46376169	shares
CY2012Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8187000	USD
CY2012Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8449000	USD
CY2012Q1	us-gaap	Assets Assets	120801000	USD
CY2012Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	442000	USD
CY2012Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5073000	USD
CY2012Q1	us-gaap	Assets Current AssetsCurrent	115286000	USD
CY2012Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2789000	USD
CY2012Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	4301000	USD
CY2012Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	83673000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24523000	USD
CY2012Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34654206	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34654206	shares
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-387000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	442000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2789000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3114000	USD
CY2011Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16970000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	770142000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3082000	USD
CY2012Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	67906000	USD
CY2011Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	71000	USD
CY2011Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	19099000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	3027000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5611000	USD
CY2012Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	313000	USD
CY2011Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	313000	USD
CY2011Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	40000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-13137000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-283241000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	525000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10483000	USD
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1476000	USD
	us-gaap	Interest Expense InterestExpense	2376000	USD
CY2012Q1	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2376000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	43000	USD
CY2011Q1	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	3432000	USD
CY2011Q1	us-gaap	Interest Expense InterestExpense	48000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5463000	USD
	fold	Preferred Stock Accretion PreferredStockAccretion	802000	USD
	fold	Deemed Dividend DeemedDividend	19424000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	231000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	14100000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-299183000	USD
	us-gaap	Operating Expenses OperatingExpenses	410421000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	418000	USD
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1030000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1522000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	117344000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	279624000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	111238000	USD
	fold	Collaboration Revenue CollaborationRevenue	59222000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13137000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13137000	USD
CY2012Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	0	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	522000	USD
CY2012Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-27000	USD
CY2012Q1	fold	Beneficial Conversion Feature Related To Bridge Financing BeneficialConversionFeatureRelatedToBridgeFinancing	0	USD
	fold	Beneficial Conversion Feature Related To Bridge Financing BeneficialConversionFeatureRelatedToBridgeFinancing	135000	USD
CY2011Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-872000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1259000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8449000	USD
CY2011Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-335000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1977000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25526000	USD
CY2011Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	30889000	USD
CY2012Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	14300000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	686390000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	143022000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62063000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	175309000	USD
CY2012Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000	USD
CY2011Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	USD
CY2012Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	837000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2548000	USD
CY2012Q1	fold	Proceeds From Exercise Of Warrants Common And Preferred ProceedsFromExerciseOfWarrantsCommonAndPreferred	0	USD
	fold	Proceeds From Exercise Of Warrants Common And Preferred ProceedsFromExerciseOfWarrantsCommonAndPreferred	264000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	5611000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	995000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4753000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29572000	USD
CY2011Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27662000	USD
CY2011Q1	us-gaap	Interest Paid InterestPaid	48000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	20000	USD
	us-gaap	Interest Paid InterestPaid	2052000	USD
CY2012Q1	fold	Conversion Of Notes Payable To Preferred Stock ConversionOfNotesPayableToPreferredStock	0	USD
	fold	Conversion Of Notes Payable To Preferred Stock ConversionOfNotesPayableToPreferredStock	5000000	USD
CY2012Q1	fold	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	0	USD
	fold	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	148951000	USD
CY2012Q1	fold	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	0	USD
	fold	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	802000	USD
CY2012Q1	fold	Beneficial Conversion Feature Related To Issuance Of Series C Redeemable Convertible Preferred Stock BeneficialConversionFeatureRelatedToIssuanceOfSeriesCRedeemableConvertiblePreferredStock	0	USD
	fold	Beneficial Conversion Feature Related To Issuance Of Series C Redeemable Convertible Preferred Stock BeneficialConversionFeatureRelatedToIssuanceOfSeriesCRedeemableConvertiblePreferredStock	19424000	USD
CY2012Q1	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
CY2012Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2012Q1	dei	Document Type DocumentType	10-Q
CY2012Q1	dei	Document Period End Date DocumentPeriodEndDate	2012-03-31
CY2012Q1	dei	Amendment Flag AmendmentFlag	false
CY2012Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46376169	shares
CY2012Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2012Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	USD
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	USD

Files In Submission

Name	View Source	Status
0001104659-12-036030-index-headers.html	Edgar Link	pending
0001104659-12-036030-index.html	Edgar Link	pending
0001104659-12-036030.txt	Edgar Link	pending
0001104659-12-036030-xbrl.zip	Edgar Link	pending
a12-9286_110q.htm	Edgar Link	pending
a12-9286_1ex31d1.htm	Edgar Link	pending
a12-9286_1ex31d2.htm	Edgar Link	pending
a12-9286_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
fold-20120331.xml	Edgar Link	completed
fold-20120331.xsd	Edgar Link	pending
fold-20120331_cal.xml	Edgar Link	unprocessable
fold-20120331_def.xml	Edgar Link	unprocessable
fold-20120331_lab.xml	Edgar Link	unprocessable
fold-20120331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2012 Q2 Form 10-Q Financial Statement

#000110465912036030 Filed on May 11, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2012 Q2 Form 10-Q Financial Statement

#000110465912036030 Filed on May 11, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold